Alpha Teknova, Inc. (TKNO) Form 10-Q — Aug 6, 2026
Alpha Teknova's Q2 2026 revenue rose 18.5% year over year to $12.2 million, with both Lab Essentials (+17.9% to $9.2 million) and Clinical Solutions (+17.9% to $2.4 million) contributing. First-half revenue reached $23.3 million, up 15.8% from $20.1 million a year earlier. Profitability improved but remains elusive. Gross margin expanded to 40.1% from 38.7%, while the quarterly net loss narrowed to $3.2 million, or $0.06 per share, from $3.6 million, or $0.07 per share, in the year-ago quarter.
Key figures
- Eps
- -$0.06 (Q2 2026); -$0.14 (H1 2026)
- Revenue
- $12.185M in Q2 2026 (+18.5% YoY); $23.262M in H1 2026 (+15.8% YoY)
- Net Income
- -$3.170M (Q2 2026); -$7.725M (H1 2026)
- Total Debt
- $13.245M term loan principal ($13.218M net) at June 30, 2026
- Revenue Yoy
- +18.5% (Q2 2026)
- Total Assets
- 95878000
- Cash Position
- $17.4M cash and short-term investments at June 30, 2026 ($6.004M cash and equivalents, $11.432M short-term investments)
- Interest Rate
- Term SOFR + 6.45% margin, subject to a 3.75% SOFR floor (Term Loan)
- Maturity Date
- March 1, 2030
- Shares Outstanding
- 53688246
- Min cash covenant
- $8.0M
- Accumulated deficit
- $143.5M
- Gross margin q2 2025
- 38.7%
- Gross margin q2 2026
- 40.1%
- Credit facility total
- $28.245M
- Revolver availability
- $3.4M
- Customer concentration
- Distributor customer A: 24% of Q2 2026 revenue, 27% of accounts receivable
- Operating loss h1 2026
- -$7.188M
- Operating loss q2 2026
- -$2.890M
- Shelf registration capacity
- $225M
- Net cash used in operating h1 2026
- -$3.830M (vs -$6.204M H1 2025)
Price after filing
Close on the filing date to close N calendar days later (from $5.52). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.